These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21518415)

  • 21. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
    Horváth JE; Zarándi M; Groot K; Schally AV
    Endocrinology; 1995 Sep; 136(9):3849-55. PubMed ID: 7649091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
    Siejka A; Schally AV; Block NL; Barabutis N
    BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benign prostatic hyperplasia - progress in pathophysiology and management.
    Dobrek Ł; Thor PJ
    Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Cai RZ; Baker B; Hammann BD; Armatis P; Kanashiro CA
    Eur J Cancer; 2005 Nov; 41(17):2735-44. PubMed ID: 16291086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
    Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
    Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
    Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
    Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research.
    Eur Urol; 1996; 29(3):374-84. PubMed ID: 8740027
    [No Abstract]   [Full Text] [Related]  

  • 35. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and medical management of benign prostatic hyperplasia.
    Beckman TJ; Mynderse LA
    Mayo Clin Proc; 2005 Oct; 80(10):1356-62. PubMed ID: 16212149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist.
    Jaffe CA; DeMott-Friberg R; Frohman LA; Barkan AL
    J Clin Endocrinol Metab; 1997 Feb; 82(2):634-7. PubMed ID: 9024267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of growth hormone-releasing hormone (GHRH) and GHRH antagonist (MZ-4-71) on interferon-gamma secretion from human peripheral blood mononuclear cells in vitro.
    Siejka A; Ławnicka H; Komorowski J; Stepień T; Krupiński R; Stepień H
    Neuropeptides; 2004 Feb; 38(1):35-9. PubMed ID: 15003714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.